期刊论文详细信息
Protein & Cell
Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy
Yuting Yang1  Zihe Rao2  Lin Cao2  Yaxin Wang2  Jie Qing3  Zhiyong Lou3  Jizheng Chen4  Xinwen Chen4 
[1] Beijing No. 166 High School;College of Pharmacy & State Key Laboratory of Medicinal Chemical Biology, Nankai University;School of Medicine and Collaborative Innovation Center of Biotherapy, Tsinghua University;State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences;
关键词: HCV;    serotonin 2A receptor;    entry;    antiviral drug;   
DOI  :  10.1007/s13238-018-0521-z
来源: DOAJ
【 摘 要 】

ABSTRACT Hepatitis C virus (HCV) is a leading cause of liver disease worldwide. Although several HCV protease/polymerase inhibitors were recently approved by U.S. FDA, the combination of antivirals targeting multiple processes of HCV lifecycle would optimize anti-HCV therapy and against potential drug-resistance. Viral entry is an essential target step for antiviral development, but FDA-approved HCV entry inhibitor remains exclusive. Here we identify serotonin 2A receptor (5-HT2AR) is a HCV entry factor amendable to therapeutic intervention by a chemical biology strategy. The silencing of 5-HT2AR and clinically available 5-HT2AR antagonist suppress cell culture-derived HCV (HCVcc) in different liver cells and primary human hepatocytes at late endocytosis process. The mechanism is related to regulate the correct plasma membrane localization of claudin 1 (CLDN1). Moreover, phenoxybenzamine (PBZ), an FDA-approved 5-HT2AR antagonist, inhibits all major HCV genotypes in vitro and displays synergy in combination with clinical used anti-HCV drugs. The impact of PBZ on HCV genotype 2a is documented in immune-competent humanized transgenic mice. Our results not only expand the understanding of HCV entry, but also present a promising target for the invention of HCV entry inhibitor.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次